ADCT ADC Therapeutics SA: חובות לטווח קצר של החברה

The share price retrospective for ADC Therapeutics (ADCT) demonstrates the asset's dynamics, with a value of 0.00. ADC Therapeutics creates potent antibody-drug conjugates for the targeted treatment of lymphomas, reducing the toxicity of hematologic tumor therapies. The company's operations are based on the development of innovative drugs and diagnostic systems to combat oncology. The startup's environmental profile is limited to laboratory chemical disposal regulations and the energy efficiency of its workspaces.

This metric is calculated by summing all liabilities with a maturity horizon of up to one year based on financial statements. It determines the current pressure on the issuer's liquidity and solvency. For ADC Therapeutics (ADCT), this volume is critical when financing the development of the PBD platform and advancing Zynlonta. The balance of borrowings affects the biotech's financial stability within the lymphoma segment. The dynamics of these liabilities on the short-term debt chart reflect the business's real margin of safety.